Exhibit 10.7

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL
TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED
COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

FIRST AMENDMENT TO

EXCLUSIVE DISTRIBUTION AGREEMENT

This First Amendment (this “Amendment”) to Exclusive Distribution Agreement is
entered into as of September 27, 2011 (the “Effective Date”), by and between
Zimmer Dental Inc., a Delaware corporation (“Zimmer”), and RTI Biologics, Inc.,
a Delaware corporation (“RTI”). Unless otherwise defined herein, capitalized
terms shall have the meanings given to them in the Agreement (as defined below).

Recitals

A.    Zimmer and RTI entered into an Exclusive Distribution Agreement on
September 30, 2010 (the “Agreement”).

B.    Zimmer and RTI desire to amend the Agreement in accordance with
Section 13.4 of the Agreement.

Agreement

For good and valuable consideration, the receipt and sufficiency of which is
acknowledged by the execution and delivery of this Amendment, Zimmer and RTI
agree to amend the Agreement as follows:

1.    Amendment to Agreement. Exhibit A to the Agreement shall be amended to
include the following additional Implants:

 

Part
Numbers
US, LA,
APR,
CAN

  

Brand/Product Description

  

Transfer Fee
US/LA/APR/CN

    

Lead
time
Calendar
Days

    

Label
Shelf
Life

    

Minimum
Shelf Life
Upon
Receipt

     Human Bone Allograft             68800    PUROS CORTICO-CANCELLOUS MIX ø
0.25-1mm, 0.5cc      [****]        [****]        [****]        [****]   68801   
PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 1cc      [****]        [****]       
[****]        [****]   68802    PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 2cc   
  [****]        [****]        [****]        [****]   68803    PUROS
CORTICO-CANCELLOUS MIX ø 1-2mm, 0.5cc      [****]        [****]        [****]  
     [****]   68804    PUROS CORTICO-CANCELLOUS MIX ø 1-2mm, 1cc      [****]  
     [****]        [****]        [****]   68805    PUROS CORTICO-CANCELLOUS MIX
ø 1-2mm, 2cc      [****]        [****]        [****]        [****]  

 

- 1 -

--------------------------------------------------------------------------------

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL
TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED
COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

2.    Development Fee. As consideration for the development of the Implants set
forth in Section 1 above, Zimmer shall pay the amount set forth on Quotation
Number 2011016 R3, attached hereto as Annex A.

3.    Effect on the Agreement. Except as specifically amended above, the
Agreement shall remain in full force and effect and is hereby ratified and
confirmed. This Amendment is being effected in accordance with Section 13.4 of
the Agreement.

[Remainder of Page Intentionally Blank]

 

- 2 -

--------------------------------------------------------------------------------

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL
TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED
COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its
respective duly authorized representative as of the Effective Date.

 

RTI BIOLOGICS, INC. By:   /s/ Roger Rose

Name:   Roger Rose

Title:   Executive Vice President

ZIMMER DENTAL, INC. By:   /s/ Harold Flynn

Name:   Harold Flynn

Title:   President

 

- 3 -

--------------------------------------------------------------------------------

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL
TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED
COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

Annex A

Quotation Product Development

 

- 4 -

--------------------------------------------------------------------------------

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL
TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED
COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

LOGO [g674465g12g61.jpg]

 

- 5 -